{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:29:12Z","timestamp":1773271752705,"version":"3.50.1"},"reference-count":18,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2013,6,14]],"date-time":"2013-06-14T00:00:00Z","timestamp":1371168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Pediatric oncology patients can experience opioid\u2010induced constipation, which may not respond to laxative treatment. Methylnaltrexone is an opioid receptor antagonist that can reverse opioid\u2010induced constipation without affecting analgesia. Published literature on the use of methylnaltrexone in children is very limited. This retrospective review describes the effectiveness and safety of methylnaltrexone for opioid\u2010induced constipation in pediatric oncology patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>A retrospective review of health records was conducted for pediatric oncology in\u2010patients who were prescribed methylnaltrexone between May 2008 and September 2012 at The Hospital for Sick Children. Demographic, clinical, efficacy, and safety data were collected, including; opioid, laxative, and methylnatrexone dosing and frequency.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifteen patients (median age: 14 years, range: 4\u201317 years) received methylnaltrexone; 12 received a single dose while three received multiple doses. At the time of methylnaltrexone administration, patients were receiving a median oral morphine dose equivalent of 5.7\u2009mg\/kg\/day (range: 1.5\u201329.2\u2009mg\/kg\/day) and had not had any bowel movements for several days despite treatment with multiple laxatives. Methylnaltrexone was given at a mean dose of 0.15\u2009\u00b1\u20090.02\u2009mg\/kg\/dose (range: 3\u201312\u2009mg\/dose) as a subcutaneous injection. After 14 of 19 doses administered, patients had a bowel movement within 4\u2009hours. Three patients had documented mild gastrointestinal upset following methylnaltrexone administration. None reported a reduction of pain control or opioid withdrawal symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case series suggests that methylnaltrexone is safe and may be effective when given subcutaneously as a 0.15\u2009mg\/kg single dose to pediatric oncology patients with opioid\u2010induced constipation. Pediatr Blood Cancer 2013;60:1667\u20131670. \u00a9 2013 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.24615","type":"journal-article","created":{"date-parts":[[2013,6,14]],"date-time":"2013-06-14T09:02:41Z","timestamp":1371200561000},"page":"1667-1670","source":"Crossref","is-referenced-by-count":31,"title":["Methylnaltrexone for Opioid\u2010Induced Constipation in Pediatric Oncology Patients"],"prefix":"10.1002","volume":"60","author":[{"given":"Amelia","family":"Rodrigues","sequence":"first","affiliation":[{"name":"Department of Pharmacy The Hospital for Sick Children Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cherie","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Hospital for Sick Children Toronto Canada"},{"name":"Division of Haematology and Oncology The Hospital for Sick Children Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Mattiussi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Hospital for Sick Children Toronto Canada"},{"name":"Division of Haematology and Oncology The Hospital for Sick Children Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Alexander","sequence":"additional","affiliation":[{"name":"Division of Haematology and Oncology The Hospital for Sick Children Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Lau","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Hospital for Sick Children Toronto Canada"},{"name":"Leslie Dan Faculty of Pharmacy University of Toronto Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Lee","family":"Dupuis","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Hospital for Sick Children Toronto Canada"},{"name":"Division of Haematology and Oncology The Hospital for Sick Children Toronto Canada"},{"name":"Leslie Dan Faculty of Pharmacy University of Toronto Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,6,14]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"551","volume-title":"Goodman & Gilman's the pharmacological basis of therapeutics","author":"Brunton LL","year":"2006"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/1043454205285874"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e318175898c"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpg.0000233159.97667.c3"},{"key":"e_1_2_6_6_1","first-page":"1347","article-title":"Management of common opioid\u2010induced adverse effects","volume":"74","author":"Swegle JM","year":"2006","journal-title":"Am Fam Physician"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1188\/08.CJON.317-337"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/11204520-000000000-00000"},{"key":"e_1_2_6_9_1","unstructured":"Compendium of Pharmaceuticals and Specialities. Methylnaltrexone product monograph.https:\/\/www\u2010e\u2010therapeutics\u2010ca.myaccess.library.utoronto.ca\/cpsPublished May 15 2011. Accessed June 20 2011."},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2010.10.015"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2011-300213"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e31822ad94c"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2012.04.001"},{"key":"e_1_2_6_14_1","first-page":"1829","volume-title":"Pediatric & neonatal dosage handbook","author":"Taketomo CK","year":"2012"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.PCC.0000216421.72002.09"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2007.12.005"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707377"},{"key":"e_1_2_6_19_1","first-page":"39","article-title":"Methylnaltrexone for treatment of opioid\u2010induced constipation in advanced illness","volume":"7","author":"Slatkin N","year":"2009","journal-title":"Support Oncol"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24615","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24615","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.24615","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T17:12:52Z","timestamp":1696525972000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.24615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,14]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1002\/pbc.24615"],"URL":"https:\/\/doi.org\/10.1002\/pbc.24615","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,14]]}}}